Xu Ying

Dr. Xu Ying


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2025 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
XYXu Ying
Xu Ying
WMWeiwei Meng
Weiwei Meng
YDYingqi Dai
Yingqi Dai
LXLin Xu
Lin Xu
NDNing Ding
Ning Ding
学庄学伟 庄
学伟 庄
Histone lactylation plays a crucial role in cancer progression, but its impact on breast cancer (BC) tumorigenesis is still unclear. We utilized chromatin immunoprecipitation sequencing with H3K18la antibodies, transcriptomics of clinical BC samples, and proteomics and ATAC-seq analyses of in vivo tumors to identify the genes regulated by H3K18la and the transcription factor PPARD. qPCR and Western blot assays were used to detect expressions of molecules. We discovered that H3K18la levels were higher in BC tissues compared to adjacent non-cancerous tissues. H3K18la promoted the expression of PPARD, which in turn influenced the transcription of AKT, but not ILK. ATAC-seq analysis revealed that glycolysis in BC cells enhanced chromatin accessibility. Additionally, we confirmed that HDAC2 and HDAC3 act as “erasers” for H3 lysine lactylation. During the proteomics analysis, AKT-phosphorylation in the aerobic respiration inhibitor group exhibited an apparent disparity and activity. Our study demonstrated that changes in H3K18la in BC and its downstream transcription factor PPARD support cell survival under anaerobic glycolysis conditions. PPARD accelerated cancer proliferation by promoting the transcription and phosphorylation of AKT. This highlights the therapeutic potential of targeting the H3K18la/PPARD/AKT axis in breast cancer, providing new insights into epigenetic regulation and cancer metabolism (Trial registration: The study was approved by the Research Ethics Committee Shandong Provincial Third Hospital (KYLL-2023057; https://www.medicalresearch.org.cn/)).

17 March 2023 in Hepatology International
Verified
Journal Article
Closed access
PDF file
XYXu Ying
Xu Ying
GLGuangchao Luan
Guangchao Luan
FLFeng Liu
Feng Liu
ZYzhang yuhua
zhang yuhua
ZLZhongchao Li
Zhongchao Li
TYTao Yang
Tao Yang

25 November 2022 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
XYXu Ying
Xu Ying
GLGuangchao Luan
Guangchao Luan
ZLZhongchao Li
Zhongchao Li
ZLZiming Liu
Ziming Liu
GQGuangyang Qin
Guangyang Qin
YCYifu Chu
Yifu Chu

10 August 2021 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
XYXu Ying
Xu Ying
HTHu Tian
Hu Tian
CLChao Guang Luan
Chao Guang Luan
KSKai Sun
Kai Sun
PBPeng Jin Bao
Peng Jin Bao
NZNan Zhang
Nan Zhang
In China, hepatocellular carcinoma (HCC) is considered a malignant tumor with poor prognosis, frequent metastasis, and a high relapse rate. Telocytes (TCs) participate in tumorigenic, invasive, and migratory processes by secreting functional proteins and transmitting cell-to-cell information, but their functions in HCC are still unknown. TC counts and MMP9 expression in liver cancer tissues were measured using immunohistochemistry, western blotting, and RT-PCR. Primary TCs from liver para-cancer tissues were cultured in vitro. To verify the role of TCs in HCC, a metastatic cancer animal model was established using three types of liver cancer cell lines in vivo. TCs promoted HCC cell metastasis by MMP9 expression in vitro and in vivo. Platelet-derived growth factor-alpha (PDGF-α), secreted by HCC cells, activated the Ras/ERK signaling pathway in TCs, thereby increasing MMP9 expression; Moreover, miR-942-3p suppressed MMP9 expression in TCs. Our results reveal the role of TCs in HCC and the mechanisms by which they elicit their effects, and they may serve as novel prognostic markers for HCC.

1 February 2021 in Acta Histochemica
Verified
Journal Article
Closed access
XYXu Ying
Xu Ying
HTHu Tian
Hu Tian
GQGuangliang Qiao
Guangliang Qiao
WZWenjie Zheng
Wenjie Zheng

23 October 2022 in Cell Biology International
Verified
Journal Article
Closed access
CLChaoguang Luan
Chaoguang Luan
XYXu Ying
Xu Ying